This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/drug/DB04574/identifier/pubchem-compound/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB04574/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB04574/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB04574/identifier/drugbank/
n9http://www.rxlist.com/
n5http://bio2rdf.org/drugbank:
n19http://www.pdrhealth.com/drugs/rx/
admshttp://www.w3.org/ns/adms#
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB04574/identifier/pharmgkb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB04574/identifier/wikipedia/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04574
rdf:type
n3:Drug
n3:description
Estropipate is a form of estrogen. It has several uses such as: Alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics,treatment of vaginal atrophy,treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis.
n3:dosage
n17:271B3FBE-363D-11E5-9242-09173F13E4C5 n17:271B3FBF-363D-11E5-9242-09173F13E4C5 n17:271B3FBD-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.
owl:sameAs
n5:DB04574 n7:DB04574
dcterms:title
Estropipate
adms:identifier
n16:D00948 n18:DB04574 n20:46508976 n21:PA165958342 n22:5284555 n23:Estropipate
n3:mechanismOfAction
Estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
n3:routeOfElimination
Estradiol, estrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates
n3:synonym
OGEN Ogen 2.5 Estropipate Ogen (TN) Estrone sulphate Estrone sulfate Estrone 3-sulfate Estrone hydrogen sulfate 3-Hydroxyestra-1,3,5(10)-trien-17-one hydrogen sulphate
n13:hasAHFSCode
n14:68-16-04
n3:foodInteraction
Take with food to decrease nausea
n11:hasConcept
n12:M0055026
foaf:page
n9:ogen-drug.htm n19:rx-mono.aspx?contentFileName=oge1308.html&contentName=Ogen&contentId=547
n3:IUPAC-Name
n6:271B3FC4-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B3FCA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B3FC9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B3FC6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B3FC7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B3FC8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B3FC2-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B3FC0-363D-11E5-9242-09173F13E4C5 n6:271B3FC3-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B3FC1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n6:271B3FD0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B3FD1-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B3FCB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B3FCC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B3FCE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B3FCD-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B3FCF-363D-11E5-9242-09173F13E4C5
n3:absorption
Estropipate is well absorbed through the skin and gastrointestinal tract. When applied for a local action, absorption is usually sufficient to cause systemic effects.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
7280-37-7
n3:category
n3:Bioavailability
n6:271B3FD6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B3FD8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B3FD9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B3FD5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B3FD4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B3FD7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B3FC5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B3FD2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B3FD3-363D-11E5-9242-09173F13E4C5